

Diagnostic criteria and prevalence of mild cognitive impairment in older adults living in the community: a systematic review and meta-analysis

REBECA MENDES P. PESSOA¹

<https://orcid.org/0000-0003-0867-1821>

ANA JULIA L. BOMFIM²

<https://orcid.org/0000-0001-7512-6343>

BIANCA L. CAVALMORETTI FERREIRA^{1,3}

<https://orcid.org/0000-0003-3639-9626>

MARCOS HORTES N. CHAGAS^{1,2,3}

<https://orcid.org/0000-0003-3752-7984>

¹ Department of Neurosciences and Behavioral Sciences, University of São Paulo (USP), São Paulo, SP, Brazil.

² Department of Psychology, Federal University of São Carlos (UFSCar), São Carlos, SP, Brazil.

³ Department of Gerontology, Federal University of São Carlos (UFSCar), São Carlos, SP, Brazil.

Received: 08/16/2018— Accepted: 04/02/2019

DOI: 10.1590/0101-60830000000197

Abstract

Background: Mild Cognitive Impairment (MCI) is a disorder in which the patient presents a cognitive decline, but without negative impact on the activities of daily living. **Objective:** To carry out a systematic review of published studies that analyzed the prevalence of Mild Cognitive Impairment (MCI) in older adults living in the community, and the criteria used for the diagnosis of this disorder. **Methods:** A search was carried out in May 2017 using the descriptors: “epidemiology” or “prevalence”, “mild cognitive impairment”, and “community” in the PubMed, PsycInfo, SciELO, Web of Science, and Scopus databases. Two independent researchers extracted and documented the data. We used a random effect model to calculate pooled prevalence of MCI for overall studies and for each subgroup divided by diagnostic criteria. **Results:** We found initially 1996 articles, and we selected 35 studies. The prevalence of MCI in the selected studies ranged from 0.5% to 41.8%. The overall pooled prevalence of MCI was 17.3% (CI 95%, 13.8–20.8), with significant heterogeneity between estimates ($I^2 = 99.6\%$). **Discussion:** The standardization of the diagnostic criteria for MCI, as well as the tests used in the cognitive evaluation, could allow the comparison between the studies and would be an important step in the researches of this area.

Pessoa RMP et al. / Arch Clin Psychiatry. 2019;46(3):72-9

Keywords: Prevalence, epidemiology, community, mild cognitive impairment.

Introduction

Mild cognitive impairment (MCI) is the term used for the disorder between cognitive age changes and early stages of dementia. Patients with this morbidity show a decline in cognitive function with respect to their baseline pattern and has no negative impact on the activities of daily living. The aim of the diagnosis of MCI is to identify individuals at the onset of cognitive decline, although not all individuals will progress to dementia^{1,2}.

MCI has received several denominations and definitions over the last 20 years, with Mayo Clinic criteria being the most accepted. The original Mayo MCI criteria evidenced memory impairment with preservation of the other cognitive domains. The criteria include memory loss, preferably corroborated by an informant; target memory impairment; general cognition preserved; preserved activities of daily living; and absence of dementia³. Later, research has expanded MCI symptomatology into other cognitive domains, and has considered memory impairment a condition not necessarily present, with the remaining criteria being better known as the Petersen Criteria³. Petersen criteria evidenced cognitive complaint, preferably corroborated by an informant; target cognitive impairment; general cognition preserved; preserved activities of daily living; and absence of dementia.

We have studies indicating a conversion of 10% to 15% per year of amnesic MCI in AD, for others MCI subtypes the conversion is still undefined, which highlights the importance of this disorder, since dementia is one of the diseases that most overburden developed countries and their health systems. Therefore, preventive measures are urgently needed⁴⁻⁶.

Despite the growing importance of MCI, studies in the area are still scarce, being a large part of them performed in clinical settings, such as reference centers for cognitive disorders, generating several implications. For example, depending on the admission mechanism of the research site, some selection criteria applied can recruit only individuals with etiology for this disorder, usually those with a degenerative origin, or with a positive family history for dementia. On the other hand, community-based studies, by definition, would not restrict the nature of the sample, but rather provide heterogeneity^{2,7}.

Therefore, the main objective of this study is to carry out a systematic review of all published studies that analyzed the prevalence of MCI in older adults living in the community, and the criteria used for the diagnosis of this disorder.

Methods

A systematic review of national and international literature, regardless of the date of publication, on the prevalence of mild cognitive impairment in communities was carried out between May 2 and 16, 2017. For this purpose, the following keywords were used: epidemiology; prevalence; mild cognitive impairment; and community. The databases used were PubMed, PsycInfo, SciELO, Web of Science, and Scopus.

Inclusion criteria were studies with: a sample aged over 60 years, performed in communities; publication in English, Portuguese and Spanish; description of criteria used for diagnosis of MCI, and of the prevalence of MCI in the results.

We excluded studies with specific clinical samples (stroke, acute myocardial infarction, etc.), which used only screening cognitive scales such as Mini-mental Status examination (MMSE), Montreal Cognitive Assessment (MoCA) or Addenbrooke's Cognitive Examination-Revised (ACE-R) to determine MCI. We also excluded letters to the editor, book chapters and reviews, collection of abstracts, comments, notes, errata, theses, dissertations, and bibliographic/systematic reviews. No time limitation was adopted.

Two independent researchers extracted and documented the following data: authorship; date, year and country of publication; study design; sample size; gender, age and schooling of participants; criteria used for diagnosis and prevalence of MCI. The data were reviewed, and any disagreement was discussed among the authors.

We evaluated the individual quality of the articles using a tool for cross-sectional studies⁸. The tool is composed of ten items that evaluate the external validity, selection, and domain of response bias, internal validity, measurement bias, and analysis. In the end, the study may be classified as low risk (score 0-3), moderate risk (4-6), or high risk (7-9). Of the 35 articles selected, five presented a moderate risk of bias⁹⁻¹³. All other articles scored between 0 and 3 (low risk).

We used a random effect model to calculate pooled prevalence of MCI for overall studies and for each subgroup divided by diagnostic criteria. We divided the diagnostic criteria into three subgroups: memory complaint plus decline in cognitive test; cognitive complaint and decline in cognitive test; and decline in cognitive test. The percentage of total variation due to heterogeneity within the subgroups and the overall was evaluated by I^2 measure. We also presented the prevalence with 95% exact confidence intervals for each study, subgroup, and overall studies. We used the Stata statistical software version 14.1 (metaprop_one command) to perform the meta-analyses.

Results

A total of 1996 articles were found. After exclusion of duplicated articles, 783 articles remained. The abstracts of these articles were reviewed, after which 748 were excluded. The final sample consisted of 35 articles. The review flowchart is shown in Figure 1.

The prevalence of MCI in the selected studies ranged from 0.5%¹⁴ to 41.8%¹⁵. The overall pooled prevalence of MCI was 17.3% (CI 95%, 13.8-20.8), with significant heterogeneity between estimates ($I^2 = 99.6\%$).

Of the included studies, 40% were published between 2000 and 2010, and 60% after 2010. Regarding the study design, 19 were cross-sectional and 16 were longitudinal studies. The sample size ranged from 42 participants in a study in Australia¹¹ to 10276 participants in a study in China¹⁶. The country with the highest number of studies was the United States, followed by China.

We divided the studies into three subgroups according to the diagnostic criteria: memory complaint plus decline in cognitive test; cognitive complaint and decline in cognitive test; and decline in cognitive test. We divided the Tables 1, 2 and 3 summarized the selected articles.

The studies differed with respect to cut-off points used in cognitive tests. For example, impairment in cognitive domains, depending on the study, was defined as a performance on tests below 1.5 standard deviation or below 1 standard deviation or below the 10th percentile relative to a reference group or below normative references.

When stratified by diagnostic criteria, the prevalence varied according to the criteria used. The studies using the memory complaint plus cognitive decline had prevalence of 15.0% (95% CI 10.4-19.7%; ranging from 0.5% to 32.6%). The studies have used only cognitive tests criteria had higher prevalence (21.6%; 95% CI 16.5-26.6%) than those used cognitive and memory complaints plus decline in cognitive tests (Figure 2). There was significant heterogeneity between prevalence estimates in all subgroups.

We also performed meta-analysis considering the following aspects: sample size (0-500; 501-1000; >1000), country *per capita* income and risk of bias. The heterogeneity of the studies remained high (>75%) in all subgroups analyzed.

In Figure 3, we presented a graph with the distribution of the studies considering the prevalence and the standard error (funnel plot). We can observe an asymmetric distribution of the studies, suggesting the presence of biases and/or even the heterogeneity of the studies. The publication bias is one of possible causes of asymmetry.




Figure 1. PRISMA flowchart. Excerpted from: Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(6):e1000097.

Table 1. Characteristics of the selected studies that used cognitive complaint plus decline in cognitive tests as diagnostic criteria

Authors	Country/GNI per capita	Year	Design	Sample	Sex (M)	Age	Schooling	Criteria	Prevalence
Afgin <i>et al.</i> (2012) ¹⁷	Israel (High)	Jan. 2003-Dec. 2008	Cohort	944 (Total: 1,003)	49.40%	MCI: 72.8 (±6.1) Healthy: 70.7 (±5.5)	3 (3) 51% illiterate	CDR 0.5	32.1% (303 subjects)
Artero <i>et al.</i> (2008) ¹⁵	France (High)	1991-2001	Cohort	6,892 (Total: 9,313)	MCI: 35% Healthy: 43.4%	MCI: 74.6 (±5.7) Healthy: 73.1 (±4.9)	Low schooling: MCI: 24.7% Healthy: 22.5%	Lowest quartile	42% (2882 subjects)
Ding <i>et al.</i> (2015) ¹⁸	China Shanghai Aging Study (Middle)	Jan. 2010-Sep. 2011	Cross-sectional	3,141 (Total: 4,519)	46% MCI: 44%	72.3 (±8.1)	Illiterate: Total: 4.26% MCI: 8.48%	1.5 SD	19.1% (601 subjects) aMCI: 12.5% (393 subjects) na-MCI: 6.6% (208 subjects)
Gao <i>et al.</i> (2014) ⁹	USA Indianapolis-Ibadan DementiaProject. (High)	1992-2009 (Seven assessments)	Cohort	2,212 (Baseline: 1,992)	35% Healthy: 36% MCI: 31.8%	74.3 (±6.9) MCI: 75.3 (±7.1) Healthy: 73.9 (±6.8)	Total: 9.7 (±3.1) MCI: 8.9 (±3.1) Healthy: 9.9 (±3)	1.5 SD	14.8% (327 subjects) Year 1992
Lee <i>et al.</i> (2009) ¹⁹	Korea GDEMCIS (High)	1st phase: Oct. 2005-March 2007	Cohort	927 (Total: 5,085)	33.7% Healthy: 34.5% MCI1: 48.9% MCI2: 18.1% MCI3: 25.9%	72.9 (±6.9) Healthy: 71.05 (±6.02) MCI1: 69.96 (±5.42) MCI2: 73.63 (±6.31) MCI3: 76.33 (±7.12)	5.2 Healthy: 6.37 (±4.87) MCI1: 7.26 (±4.39) MCI2: 2.57 (±3.17) MCI3: 3.24 (±4.41)	Cutoffs	7.6% (all types of MCI) (384 subjects)
Ogunniyi <i>et al.</i> (2016) ²⁰	Nigeria (Middle)	May-Oct. 2013 Jan.-Feb. 2014	Cohort	613 (Total: 642)	30.3% Healthy: 31.7% MCI: 19.8%	72.9 (±8.5)	Literate: Healthy: 33.6% MCI 13.5%	Cutoffs	18.1% (111 subjects) SDa-MCI: 42.3% MDa-MCI: 40.5% SDna-MCI: 16.2% MDna-MCI: 0.9%
Olazarán <i>et al.</i> (2015) ¹²	Spain The Vallecas Project (High)	Oct. 2011-Dec. 2013	Cohort	1,169 (Total: 2,077)	36.5%	Total: 74.4 (±3.9)	< Primary school Total: 18.6%	1.5 SD	MCI: 7% (82 subjects) aMCI: 3.1% naMCI: 0.1% mixed MCI: 3.8%
Petersen <i>et al.</i> (2010) ²¹	USA The Mayo Clinic Study of Ageing (High)	Oct. 2004-July 2007	Cohort	2,050 (Total: 4,398)	MCI: 58.35%	-	-	1.0 SD	16% (329 subjects) SDa-MCI: 11.6% MDa-MCI: 4.5% SDna-MCI: 3.4% MDna-MCI: 1.1%
Pilleron <i>et al.</i> (2015) ²²	Central Africa CAR: Central African Republic ROC: Republic of the Congo (Low)	Nov. 2011-Dec. 2012	Cross-sectional	2,002 CAR: 973 ROC: 1029	CAR: 37.9% ROC: 39.2%	CAR: 72.7 (±6.5) ROC: 73.8 (±6.9)	Illiterate: Total: CAR: 69.2% ROC: 68.4%	Cutoffs	6.6% (133 subjects) 7.2(CAR) (70 subjects) 6.1% (ROC) (63 subjects)
Richard <i>et al.</i> (2013) ²³	USA WHICAP (High)	1999-2001	Cohort	2,160 (Total: 2,183)	-	-	-	-	19.86% (429 subjects) 51.7% aMCI 48.3% naMCI
Tiwari <i>et al.</i> (2013) ²⁴	India (Middle)	2008-2010	Cross-sectional	2,146 (Total: 2,324)	Total: 47.4%	Total: 67.8 (±5.9)	-	-	4.6% (99 subjects)
Vanoh <i>et al.</i> (2017) ²⁵	Malaysia TUA (Middle)	4 years long	Longitudinal	1,993	Total: 50.3% MCI: 56.5%	Total: 68.51 (±5.93) MCI: 69.45 (±5.98)	Total: 5.54 (±3.94) MCI: 4.62 (±3.18)	1.5 SD	16% (315 subjects)
Yu <i>et al.</i> (2016) ²⁶	China (Middle)	-	Cohort	376 (Total: 480)	-	Healthy: 68.3 (±4.1) MCI: 68.6 (±4.7)	Healthy: 8 (±4.3) MCI: 7.1 (±4.2)	-	17.6% (66 subjects)

GNI: Gross National income; MCI: mild cognitive impairment; CDR: clinical dementia rating; SD: standard deviation; aMCI: amnesic mild cognitive impairment; naMCI: nonamnesic mild cognitive impairment; SDa-MCI: single-domain amnesic MCI; MDa-MCI: multiple-domain amnesic MCI; SDna-MCI: single-domain non-amnesic MCI; MDna-MCI: multiple-domain amnesic.

Table 2. Characteristics of the selected studies that used memory complaint plus decline in cognitive tests as diagnostic criteria

Authors	Country/ GNI per capita	Year	Design	Sample	Sex (M)	Age	Schooling	Criteria	Prevalence
Choi <i>et al.</i> (2008) ²⁷	Korea (High)	July 2005- Feb. 2007	Cross- sectional	175 (Total: 1,215)	53.2% Healthy: 2% MCI: 59.6%	Total: 74.3 (±16.7) MCI: 73.82 (±4.51) Healthy: 71.88 (±4.17)	MCI: 4.93(±3.27) Healthy: 5.85 (±4.63)	CDR 0.5	32.9% (57 subjects)
Juarez- Cedillo <i>et al.</i> (2012) ²⁸	Mexico SADEM (Middle)	Sep. 2009-March 2010	Cross- sectional	3,036 (Total: 3,191)	42% MCI: 36.3% Healthy: 42.6%	71.2 (±7.5) MCI: 75.3 (±7.9) Healthy: 70.9 (±7.3)	Total: 6.1 (±4.6) MCI: 5.4 (±5.5) Healthy: 6.2 (±4.6)	1.5 SD	6.25% (190 subjects) SDa-MCI: 2.41% MDa-MCI: 2.56% SDna-MCI: 1.18% MDna-MCI: 0.3%
Jungwirth <i>et al.</i> (2005) ¹⁴	Austria VITA (High)	Start in May 2000	Cross- sectional	592 (Total: 1,505)	Memory only: 50% Only lack of memory: 30.7% Memory + lack of memory: 25.8% Petersen: 66.7%	Memory only: 75.71 (±0.44) Lack of memory only: 75.83 (±0.46) Memory + lack of memory: 75.89 (±0.46) Petersen: 75.3 (±0.2)	Memory only: 10.5 (±1.9) Lack of memory only: 9.5(±2) Memory + lack of memory: 9.4 (±1.6) Petersen: 9.7 (±2.1)	1.5 SD	Memory only: 3.7% (22 subjects) Lack of memory only: 14.9% (88 Subjects) Memory + lack of memory: 5.2% (31 subjects) Petersen- MCI- amnestic: 0.5% (3 subjects)
Katz <i>et al.</i> (2012) ²⁹	USA Einstein Aging Study (High)	1993-2004	Cohort	1,944	39.3%	78.8 (±5.42)	Total: 13.5 (±3.5)	1.5 SD	20% (390 subjects) aMCI: 11.6% (226 subjects) naMCI: 9.9%
Khedr <i>et al.</i> (2015) ³⁰	Egypt (Middle)	Sep. 2011- Aug. 2013	Cross- sectional	691	MCI: 58%	MCI: 67.3 (±7.1)	Illiterate: MCI: 66%	1.5 SD	1.74% (12 subjects)
Kumar <i>et al.</i> (2005) ³¹	Australia PATH 60 + (High)	1st phase: 2001/2002	Cohort	2,518 (Total: 4,378)	-	-	13.72	Cutoffs	MCI: 3.7% (93 subjects) MND: 0,6% (15 subjects)
Lee <i>et al.</i> (2009) ³²	Korea KLoSHA (High)	2005	Cross- sectional	714	32.2%	71.9 (±5.7)	< 6 years of schooling: Total: 50.7%	1.5 SD	SMC: 27.59% (197 subjects) CDR 0.5: 17.9% (aMCI: 59.9% and naMCI: 40.1%)
Lee <i>et al.</i> (2012) ³³	Malaysia (Middle)	Dec. 2008- May 2009	Cross- sectional	318 (Total: 333)	40.9%	65.9 (±5.3)	Total: 5.8 (±3.5)	1.5 SD	MCI: 21.1% (67 subjects) aMCI: 15.4% (49 subjects) naMCI: 5.7%
Louis <i>et al.</i> (2005) ³⁴	USA (High)	1992/1999- 2001	Cohort	2,230 (Total: 2,776)	32.5% Healthy: 32% a-MCI: 34.5% na-MCI: 33.3%	77.2 (±6.6) Healthy: 77 (±6.6) a-MCI: 78.1 (±7) na-MCI: 77.1 (±6.6)	10.3 (±4.8) Healthy: 10.5 (±4.7) a-MCI: 10.2 (±4.6) na- MCI: 9.6 (±5)	1.5 SD	27.3% (aMCI 42% and na MCI: 58%) (608 subjects)
Ma <i>et al.</i> (2016) ³⁵	China (Middle)	Jan.-May 2012	Cross- sectional	5,214 (Total: 5,291)	43.9% Healthy: 42.19% MCI: 40.4%	72.13 (±4.22)	6.34 (±7.26)	1.5 SD	11.33% (574 subjects) SDa-MCI: 4.48% (227 subjects) MDa-MCI: 2.09% (106 subjects) SDna-MCI: 4.22% (214 subjects) MDna-MCI: 0.53% (27 subjects)
Purser <i>et al.</i> (2005) ³⁶	USA EPESE (High)	1981, 1984, 1987, 1991	Cohort	3,673	39.7%	74	Total: 11	Cutoffs	22% (810 subjects)
Shimada <i>et al.</i> (2013) ³⁷	Japan OSHPE (High)	2011/2012	Cross- sectional	5,025 (Total: 5,104)	Healthy: 39.9% MCI: 48.2%	-	-	1.5 SD	18.8% (945 subjects)
Wang <i>et al.</i> (2015) ³⁸	China (Middle)	Jan. 2010- Jan. 2011	Cross- sectional	3,136	Total: 40.65%	Total: 69.3 (±6.8)	-	1.5 SD	20% (625 subjects)

GNI: Gross National income; MCI: mild cognitive impairment; CDR: clinical dementia rating; SD: standard deviation; SDa-MCI: single-domain amnestic MCI; MDa-MCI: multiple-domain amnestic MCI; SDna-MCI: single-domain non-amnestic MCI; MDna-MCI: multiple-domain amnestic; aMCI: amnestic mild cognitive impairment; naMCI: nonamnestic mild cognitive impairment; MND: mild neurocognitive disorder; SMC: subjective memory complaint.

Table 3. Characteristics of the selected studies that used decline in cognitive tests as diagnostic criteria

Authors	Country/GNI per capita	Year	Design	Sample	Sex (M)	Age	Schooling	Criteria	Prevalence
César <i>et al.</i> (2016) ³⁹	Brazil (Middle)	2012	Cross-sectional	630 (Total: 738)	37% Healthy: 34.3% MCI: 39.3%	71.28 (±7.99) MCI: 72.44 (±7.72) Healthy: 69.26 (±7.03)	Total: 4.9 (±4.54) MCI: 4.23 (±4.16) Healthy: 5.61 (±4.83)	Cutoffs	19.5% (135 subjects)
Hilal <i>et al.</i> (2013) ⁴⁰	Singapore EDIS (High)	Aug. 2010-Feb. 2012.	Cross-sectional	1,226 (Total: 1,538)	-	Total: 68.2	-	1.5 SD	13.3% (164 subjects) Mild MCI: 6.9% (84 subjects) Moderate MCI: 6.5% (80 subjects)
Hughes <i>et al.</i> (2012) ⁴¹	USA MYHAT (High)	2006-2008	Cross-sectional	1,737 (Total: 1,982)	37.3% Healthy: 37.7% MCI: 37.6%	77.23 (±7.33) MCI: 77.72 (±7.38) Healthy: 76.95 (±7.29)	≤ High school: Total: 13.24% MCI: 12.84% Healthy: 13.46%	Normative reference	35.9% (623 subjects) *78: SDa-MCI *136: MDa-MCI *289: SDna-MCI *120: MDna-MCI
Jager and Budge (2005) ¹⁰	UK (High)	4 year of study, with 3 assessments	Cohort	157	-	-	-	1.5 SD	25.5% T1 (40 subjects)
Jia <i>et al.</i> (2013) ¹⁶	China (Middle)	Oct. 2008-Oct. 2009	Cross-sectional	10,276 (59.3% urban area and 40.6% rural area) (Total: 13,806)	(Urban: 43.2% Rural: 41.8%)	-	Illiterate: Total: (Urban: 17.7% Rural: 48.2%)	1.5 SD	20.8% (2137 subjects) Urban: 17% Rural: 25.1%
Low <i>et al.</i> (2004) ¹¹	Australia (High)	-	Cross-sectional	42 (Total: 127)	59.5% Healthy: 63% MCI: 50%	74.38 (±2.47) Healthy: 73.3 (±2.4) MCI: 75.5 (±2.2)	11.26 (±3.2) Healthy: 11.8 (±3.1) MCI: 10.3 (±3.4)	1.5 SD	11% MCI (14 subjects) 3.14% aMCI (4 subjects)
Paddick <i>et al.</i> (2015) ⁴²	Tanzania (Middle)	April-Sep. 2009	Cross-sectional	296	MCI: 21.7%	MCI: 82	-	Normative reference	15.5% (46 subjects)
Saxton <i>et al.</i> (2009) ⁴³	USA GEM (High)	Assessments every 6 months	Cohort	3,063	53.8% Healthy: 52.4% CDR: 57.8% NP: 54.9% CDR+NP: 50.6%	78.5 (±3.3) Healthy: 78 (±2.9) CDR: 78.7 (±3.4) NP: 78.7 (±3.5) CDR+NP: 79.6 (±3.7)	Healthy: 14.5 (±2.8) CDR: 13.8 (±2.8) NP: 15 (±3.1)	1.5 SD	CDR: 40.2% (1232 subjects) NP: 28.1% (861 subjects) CDR+NP: 15.7% (480 subjects)
Trittschuh <i>et al.</i> (2011) ⁴⁴	USA ACT (High)	2007	Cross-sectional	159 (Total: 200)	40.9%	80.2 (±6.5)	15.4 (±3.2)	Factor 1: standard vs. individual cut-off points Factor 2: Severity of the impairment (1vs1.5) Factor 3: one vs. mean.	11.3%-91.8% SDa-MCI: 2.5-10.7% MDa-MCI: 1.9-61%

GNI: Gross National income; MCI: mild cognitive impairment; CDR: clinical dementia rating; SD: standard deviation; SDa-MCI: single-domain amnesic MCI; MDa-MCI: multiple-domain amnesic MCI; SDna-MCI: single-domain non-amnesic MCI; MDna-MCI: multiple-domain amnesic; aMCI: amnesic mild cognitive impairment; NP: neuropsychological tests.




Figure 2. Forest plot for prevalence of mild cognitive impairment in the community stratified by diagnostic criteria.




Figure 3. Distribution of the studies considering the prevalence and the standard error (funnel plot).

Discussion

The present study showed that prevalence rates of MCI in the community can have a large variation. Differences in the characteristics of the studies, such as mean age and schooling of the sample, diagnostic criteria, cognitive tests used, and operationalization of these criteria, may account for this variability.

The studies, even when divided according to the same diagnostic criteria used for MCI, presented high heterogeneity, precluding a valid prevalence. These results can vary considerably from each other, because of the sample definition and how the procedures are performed. This fact hinders a comparison between the studies, emphasizing the need for standardized criteria.

Despite the heterogeneity found, an important feature of the present review was the use of community-based studies alone. In this type of study, shorter assessments with screening tests that can generate erroneous data are usually chosen. A refined clinical evaluation is often needed for MCI diagnosis². Another aspect to be taken into account is that voluntary participation is more significant in community studies than those conducted in academic settings, such as hospitals or clinics, what facilitates the adherence of participants. Especially in the case of more advanced ages, which correspond to the MCI profile, patients who refuse to participate in studies likely have stronger cognitive impairment than the participants⁴⁵. Another limitation of the study was the non-use of grey literature, which could generate a publication bias.

Regarding the method for diagnosis of MCI, when only cut-off points in neuropsychological assessment were used to determine prevalence rates, without a clinical evaluation, higher values were found, such as the method used in the study of Tritschchuch *et al.* (2016), that reported a prevalence of 91.8%. This study tested different cut-off points for neuropsychological tools, like standard versus individualized, severity of impairment (1.0 versus 1.5 SD), and level of impairment (any versus average).

Diagnosis based only on neuropsychological assessment does not consider essential criteria for MCI as clinical complaints and the absence of loss of functionality. It is important to emphasize that, although scales are useful in certain environments, they have several limitations and should not be equated with clinical criteria².

The concomitant use of clinical evaluation and neuropsychological status resulted in lower MCI prevalence rates compared to the studies that used only decline in cognitive tests. However, the criterion of subjective cognitive complaints may be disadvantageous in studies not performed in selective samples of memory clinics, since a large percentage of individuals with memory impairments do not express complaints related to this and cognitive complaints may be associated with other pathologies, such as anxiety and depressive disorders⁴⁶. On the other hand, subjective cognitive complaints are usually the only sign of incipient cognitive deterioration in people with high schooling who do not show impairment in cognitive performance if a degree of dementia occur in people with higher schooling, these situations are more advanced and associated with a faster cognitive decline than in people with low schooling^{5,47}.

Only two studies used the Clinical Dementia Rating (CDR) value of 0.5 along with medical history as diagnostic criteria. CDR is a scale that ranges from normal (CDR 0) to questionable dementia (CDR 0.5) and then to various stages of dementia, mild (CDR 1), moderate (CDR 2) and severe (CDR 3). Some studies consider CDR 0.5 as MCI; nevertheless, it is important to note that CDR is not a diagnostic tool, but rather a severity scale. Therefore, individuals with CDR 0.5 can meet both MCI and mild dementia criteria².

Therefore, it is advisable that cognitive decline be assessed through various and objective tests rather than a single subjective or punctual objective assessment⁴⁵. Furthermore, since the course of changes in normal individuals is variable and tool-dependent a good diagnostic anamnesis, especially in the case of pathologies such as MCI, is necessary along with screening tests⁴⁶.

This review also highlights the importance of standardization for operationalization of MCI criteria, such as in what concerns objective cognitive impairment. Core clinical criteria for MCI (due to Alzheimer Disease) include cognitive impairment in one or more domains compared to appropriate normative data with a suggested deficit level of 1.0-1.5 SD below normative expectations⁴⁸. If this is defined as a performance below 1.5 standard deviations below the mean of the reference group, the prevalence of MCI, from pure statistical reasons, will be lower than if the criterion is performance below 1 standard deviation. Moreover, studies with a short cognitive battery may fail to diagnose cases of lighter MCI due to low sensitivity, leading to false-negative cases⁵.

Although current most used criteria provide guidance on an operational definition of cognitive impairment in MCI, the literature reveals great variability in how MCI has been defined.

Slight alterations to the operational criteria for neuropsychological impairment in MCI can result in anywhere from 10 to 74% of samples being identified as MCI⁴⁹.

The criteria for MCI diagnosis should be better standardized, as well as their operation, to facilitate the comparability of different epidemiological and clinical findings. This would probably generate a greater stability of this disorder with the consequent identification of high-risk populations for developing dementia, and earlier possibility to onset of drug treatment. Large longitudinal studies are needed to document the evolution of these individuals².

Conclusions

A total of 35 studies were selected in this systematic review. The prevalence of MCI ranged from 0.5% to 41.8%, with the overall pooled prevalence of 17.3%. This heterogeneity in the results may be a result of differences in the characteristics of the studies, such as sample age, schooling, diagnostic criteria used, and operationalization of these criteria. MCI diagnostic criteria need to be better standardized, allowing the comparison among the studies.

Acknowledgements

Ana Julia L. Bomfim is a recipient of a scholarship from the Coordination of Improvement of Higher Level Personnel/Capes, Brazil (Financial code 001).

Disclosure

The authors declare no conflict of interest.

References

- Knopman DS, Petersen RC. Mild cognitive impairment and mild dementia: a clinical perspective. *Mayo Clin Proc.* 2014;89(10):1452-9.
- Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med.* 2004;256(3):183-94.
- Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik R, et al. Mild cognitive impairment: ten years later. *Arch Neurol.* 2009;66(12):1447-55.
- Dawe B, Procter A, Philpot M. Concepts of mild memory impairment in the elderly and their relationship to dementia: a review. *Int J Geriatr Psychiatry.* 1992;7(7):473-9.
- Luck T, Luppá M, Briel S, Riedel-Heller SG. Incidence of mild cognitive impairment: a systematic review. *Dement Geriatr Cogn Disord.* 2010;29(2):164-75.
- Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current Concepts in Mild Cognitive Impairment. *Arch Neurol.* 2001;58(12):1985-92.
- Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. *Neurology.* 2001;56(1):37-42.
- Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. *J Clin Epidemiol.* 2012;65(9):934-9.
- Gao S, Unverzagt FW, Hall KS, Lane KA, Murrell JR, Hake AM, et al. Mild Cognitive Impairment, Incidence, Progression, and Reversion: Findings from a Community-based Cohort of Elderly African Americans. *Am J Geriatr Psychiatry.* 2014;22(7): 670-81.
- Jager CA, Budge MM. Stability and predictability of the classification of mild cognitive impairment as assessed by episodic memory test performance over time. *Neurocase.* 2005;11(1):72-9.
- Low LF, Brodaty H, Edwards R, Kochan N, Draper B, Trollor J, et al. The prevalence of "cognitive impairment no dementia" in community-dwelling elderly: a pilot study. *Aust N Z J Psychiatry.* 2004;38(9):725-31.
- Olazarán J, Valentí M, Frades B, Zea-Sevilla MA, Ávila-Villanueva M, Fernández-Blázquez MÁ, et al. The Valdecas Project: A cohort to identify early markers and mechanisms of Alzheimer's disease. *Front Aging Neurosci.* 2015;7(181):1-10.
- Trittschuh EH, Crane PK, Larson EB, Cholerton B, McCormick WC, McCurry SM, et al. Effects of varying diagnostic criteria on prevalence of mild cognitive impairment in a community based sample. *J Alzheimers Dis.* 2011;25(1):163-73.
- Jungwirth S, Weissgram S, Zehetmayer S, Tragl KH, Fischer P. VITA: Subtypes of mild cognitive impairment in a community-based cohort at the age of 75 years. *Int J Geriatr Psych.* 2005;20(5):452-8.
- Artero S, Ancelin ML, Portet F, Dupuy A, Berr C, Dartigues JF, et al. Risk profiles for mild cognitive impairment and progression to dementia are gender specific. *J Neurol Neurosurg Psychiatry.* 2008;79(9):979-84.
- Jia J, Zhou A, Wei C, Jia X, Wang F, Li F, et al. The prevalence of mild cognitive impairment and its etiological subtypes in elderly Chinese. *Alzheimers Dement.* 2013;10(4):439-47.
- Afgin AE, Massarwa M, Schechtman E, Israeli-Korn SD, Strugatsky R, Abufuf A, et al. High prevalence of mild cognitive impairment and Alzheimer's disease in Arabic villages in northern Israel: impact of gender and education. *J Alzheimers Dis.* 2012;29(2):431-9.
- Ding D, Zhao Q, Guo Q, Meng H, Wang B, Luo J, et al. Prevalence of mild cognitive impairment in an urban community in China: a cross-sectional analysis of the Shanghai Aging Study. *Alzheimers Dement.* 2015;11(3):300-9.
- Lee KS, Cheong HK, Oh BH, Na DL, Hong CH. Working criteria of mild cognitive impairment in community: findings from Gwangju Dementia and Mild Cognitive Impairment Study (GDEM-CIS). *Asia-Pacific Psychiatry.* 2009;1(1):15-22.
- Ogunniyi A, Adebisi AO, Adediran AB, Olakehinde OO, Siwoku AA. Prevalence estimates of major neurocognitive disorders in a rural Nigerian Community. *Brain Behav.* 2016;6(7): e00481.
- Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS, et al. Prevalence of mild cognitive impairment is higher in men The Mayo Clinic Study of Aging. *Neurology.* 2010;75(10):889-97.
- Pilleron S, Jésus P, Desport JC, Mbelesso P, Ndamba-Bandzouzi B, Clément JP, et al. Association between mild cognitive impairment and dementia and undernutrition among elderly people in Central Africa: some results from the EPIDEMCA (Epidemiology of Dementia in Central Africa) programme. *Br J Nutr.* 2015;114(2):306-15.
- Richard E, Reitz C, Honig LH, Schupf N, Tang MX, Manly JJ, et al. Late-life depression, mild cognitive impairment, and dementia. *JAMA Neurol.* 2013;70(3):374-82.
- Tiwari SC, Srivastava G, Tripathi RK, Pandey NM, Agarwal GG, Pandey S, et al. Prevalence of psychiatric morbidity amongst the community dwelling rural older adults in northern India. *Indian J Med Res.* 2013;138(4):504-14.
- Vanoh D, Shahar S, Din NC, Omar A, Vyrn CA, Razali R, et al. Predictors of poor cognitive status among older Malaysian adults: baseline findings from the LRGS TUA cohort study. *Aging Clin Exp Res.* 2017; 29(2):173-82.
- Yu J, Lam CLM, Lee TMC. Perceived loneliness among older adults with mild cognitive impairment. *Int Psychogeriatr.* 2016;28(10):1681-5.
- Choi SJ, Jung SS, You YS, Shin BS, Kim JE, Yoon SW, et al. Prevalence of Alzheimer's dementia and its risk factors in community-dwelling elderly Koreans. *Psychiatry Investig.* 2008;5(2):78-85.
- Juarez-Cedillo T, Sanchez-Arenas R, Sanchez-Garcia S, Garcia-Penaa C, Hsiung GYR, Sepelhy AA, et al. Prevalence of mild cognitive impairment and its subtypes in the Mexican population. *Dement Geriatr Cogn Disord.* 2012;34(5-6):271-81.
- Katz MJ, Lipton RB, Hall CB, Zimmerman ME, Sanders AE, Verghese J, et al. Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and Alzheimer dementia in blacks and whites: a report from the Einstein Aging Study. *Alzheimer Dis Assoc Disord.* 2012;26(4):335-43.
- Khedr E, Fawi G, Abbas MA, Mohammed TA, El-Fetoh NA, Al Attar G, et al. Prevalence of mild cognitive impairment and dementia among the elderly population of Qena Governorate, Upper Egypt: a community-based study. *J Alzheimers Dis.* 2015;45(1):117-26.
- Kumar R, Dear KBG, Christensen H, Ilschner S, Jorm AF, Meslin C, et al. Prevalence of mild cognitive impairment in 60 to 64-year-old Community-dwelling individuals: The Personality and Total Health through Life 60+ Study. *Dement Geriatr Cogn Disord.* 2005;19(2-3):67-74.
- Lee SB, Kim KW, Youn JC, Park JH, Lee JJ, Kim MH, et al. Prevalence of mild cognitive impairment and its subtypes are influenced by the

- application of diagnostic criteria: results from the Korean Longitudinal Study on Health and Aging (KLoSHA). *Dement Geriatr Cogn Disord*. 2009;28(1):23-9.
33. Lee LK, Shahar S, Chin AV, MohdYusoff NA, Rajab N, Aziz SA. Prevalence of gender disparities and predictors affecting the occurrence of mild cognitive impairment (MCI). *Arch Gerontol Geriatr*. 2012;54(1):185-91.
 34. Louis ED, Schupf N, Manly J, Marder K, Tang MX, Mayeux R. Association between mild parkinsonian signs and mild cognitive impairment in a community. *Neurology*. 2005;64(7):1157-61.
 35. Ma F, Wu T, Zhao J, Ji L, Song A, Zhang M, et al. Prevalence of mild cognitive impairment and its subtypes among Chinese older adults: role of vascular risk factors. *Dement Geriatr Cogn Disord*. 2016;41(5-6):261-72.
 36. Purser JL, Fillenbaum GG, Pieper CF, Wallace RB. Mild cognitive impairment and 10-year trajectories of disability in the Iowa Established Populations for Epidemiologic Studies of the Elderly cohort. *J Am Geriatr Soc*. 2005;53(11):1966-72.
 37. Shimada H, Makizako H, Doi T, Yoshida D, Tsutsumimoto K, Anan Y, et al. Combined prevalence of frailty and mild cognitive impairment in a population of elderly Japanese people. *J Am Med Dir Assoc*. 2013;14(7):518-24.
 38. Wang Y, Song M, Yu L, Wang L, An C, Xun S, et al. Mild cognitive impairment: vascular risk factors in community elderly in four cities of Hebei Province, China. *PLoS One*. 2015;10(5):e0124566.
 39. César KG, Brucki SMD, Takada LT, Nascimento LFC, Gomes CMS, Almeida MCS, et al. Prevalence of cognitive impairment without dementia and dementia in Tremembé, Brazil. *Alzheimer Dis Assoc Disord*. 2016;30(3):264-71.
 40. Hilal S, Ikram MK, Saini M, Tan CS, Catindig JA, Dong YH, et al. Prevalence of cognitive impairment in Chinese: epidemiology of dementia in Singapore study. *J Neurol Neurosurg Psychiatry*. 2013;84(6):686-92.
 41. Hughes TF, Chang CCH, Bilt JV, Snitz BE, Ganguli M. Mild cognitive deficits and everyday functioning among older adults in the community: The Monongahela-Youghioheny healthy aging team study. *Am J Geriatr Psychiatry*. 2012;20(10):836-44.
 42. Paddick S, Kisoli A, Samuel M, Higginson J, Gray WK, Dotchin CL, et al. Mild Cognitive Impairment in Rural Tanzania: Prevalence, Profile, and Outcomes at 4-Year Follow-up. *Am J Geriatr Psychiatry*. 2015;23(9):950-9.
 43. Saxton J, Snitz BE, Lopez OL, Ives DG, Dunn LO, Fitzpatrick A, et al. Functional and cognitive criteria produce different rates of mild cognitive impairment and conversion to dementia. *J Neurol Neurosurg Psychiatry*. 2009;80(7):737-43.
 44. Trittschuh EH, Crane PK, Larson EB, Cholerton B, McCormick WC, McCurry SM, et al. Effects of varying diagnostic criteria on prevalence of mild cognitive impairment in a community based sample. *J Alzheimers Dis*. 2011;25(1):163-73.
 45. Luck T, Riedel-Heller SG, Kaduszkiewicz H, Bickel H, Jessen F, Pentzek M, et al. Mild cognitive impairment in general practice: age-specific prevalence and correlate results from the German study on ageing, cognition and dementia in primary care patients (AgeCoDe). *Dement Geriatr Cogn Disord*. 2007;24(4):307-16.
 46. Ivnik R, Smith G, Lucas J, Petersen RC, Boeve BF, Kokmen E, et al. Testing normal older people three or four times at 1- to 2-year intervals: defining normal variance. *Neuropsychology*. 1999;13:121-7.
 47. Bickel H, Mösch E, Seigerschmidt E, Siemen H, Förstl H. Prevalence and persistence of mild cognitive impairment among elderly patients in general hospitals. *Dement Geriatr Cogn Disord*. 2006;21(4):242-50.
 48. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):270-9.
 49. Jak AJ, Bondi MW, Delano-Wood L, Wierenga C, Corey-Bloom J, Salmon DP, et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. *Am J Geriatr Psychiatry*. 2009;17(5):368-75.